United States Biotechnology & Medical Research

AVITA Medical Inc (RCEL)

Track

Over the past 90 days, AVITA Medical Inc. has seen 13 insider buy transactions totaling $246,534.50, with no recorded sales. Notable activity includes consistent purchasing by Woody Joseph Fralin and CFO David D. O'Toole. This buying follows the company's May 2026 earnings report, which missed EPS expectations by 26.3%.
Ticker: RCEL Exchange: NAS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for AVITA Medical Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Buy 9 Jun 2026
Value US$4,127,039.89 | Price 351.42 | Shares 63,262 (-15.8%)
Buy 9 Jun 2026
Value US$2,390,570.20 | Price 449.30 | Shares 39,790 (-43.0%)
Buy 9 Jun 2026
Value US$21,000.00 | Price 4.20 | Shares 5,000 (+5.4%)
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-06-10 2026-06-09 B Purchase
1.9
Woody Joseph Fralin
Non-Executive Director
63,262 -15.8%
351.42
US$4,127,040 		63,262 -15.8% 351.42 US$4,127,040
2026-06-09 2026-06-09 B Purchase
1.9
Woody Joseph Fralin
Non-Executive Director
39,790 -43.0%
449.30
US$2,390,570 		39,790 -43.0% 449.30 US$2,390,570
2026-06-09 2026-06-09 B Purchase
1.9
Woody Joseph Fralin
Non-Executive Director
99,199 -7.9%
168.51
US$1,287,339 		99,199 -7.9% 168.51 US$1,287,339
2026-06-05 2026-06-03 B Purchase
1.9
Woody Joseph Fralin
Non-Executive Director
5,000 +5.7%
4.09
US$20,450 		5,000 +5.7% 4.09 US$20,450
2026-06-05 2026-06-03 B Purchase
1.9
Woody Joseph Fralin
Non-Executive Director
5,000 +5.7%
4.09
US$20,450 		5,000 +5.7% 4.09 US$20,450
2026-06-05 2026-06-03 B Purchase
1.9
Woody Joseph Fralin
Non-Executive Director
5,000 +6.0%
4.10
US$20,500 		5,000 +6.0% 4.10 US$20,500
2026-06-05 2026-06-03 B Purchase
1.9
Woody Joseph Fralin
Non-Executive Director
5,000 +6.0%
4.10
US$20,500 		5,000 +6.0% 4.10 US$20,500
2026-06-03 2026-06-02 B Purchase
1.9
Woody Joseph Fralin
Non-Executive Director
5,000 +33.3%
4.21
US$21,035 		5,000 +33.3% 4.21 US$21,035
2026-06-03 2026-06-02 B Purchase
1.9
Woody Joseph Fralin
Non-Executive Director
5,000 +50.0%
4.18
US$20,901 		5,000 +50.0% 4.18 US$20,901
2026-06-03 2026-06-01 B Purchase
1.9
Woody Joseph Fralin
Non-Executive Director
5,000 +100.0%
4.26
US$21,300 		5,000 +100.0% 4.26 US$21,300
2026-06-03 2026-06-01 B Purchase
1.9
Woody Joseph Fralin
Non-Executive Director
5,000 +inf%
4.34
US$21,700 		5,000 +inf% 4.34 US$21,700
2026-05-20 2026-05-20 B Purchase
2.7
O'Toole David D

CFO

Officer
2,000 +1.4%
4.26
US$8,520 		2,000 +1.4% 4.26 US$8,520
2026-05-19 2026-05-19 B Purchase
2.7
O'Toole David D

CFO

Officer
2,000 +1.4%
4.24
US$8,480 		2,000 +1.4% 4.24 US$8,480
2026-03-11 2026-03-11 B Purchase
2.7
O'Toole David D

CFO

Officer
1,800 +1.3%
4.78
US$8,604 		1,800 +1.3% 4.78 US$8,604
2026-02-23 2026-02-19 B Purchase
2.7
O'Toole David D

CFO

Officer
3,000 +2.2%
4.15
US$12,450 		3,000 +2.2% 4.15 US$12,450
2025-08-29 2025-08-28 B Purchase
1.7
McNamara Robert
Non-Executive Director
10,000 +13.0%
4.50
US$45,000 		10,000 +13.0% 4.50 US$45,000
2025-08-26 2025-08-26 B Purchase
2.7
O'Toole David D

CFO

Officer
2,000 +6.7%
4.52
US$9,040 		2,000 +6.7% 4.52 US$9,040
2025-08-20 2025-08-19 B Purchase
1.7
McNamara Robert
Non-Executive Director
10,000 +15.0%
5.00
US$50,000 		10,000 +15.0% 5.00 US$50,000
2025-08-12 2025-08-12 B Purchase
2.7
O'Toole David D

CFO

Officer
2,000 +7.2%
4.81
US$9,620 		2,000 +7.2% 4.81 US$9,620
2025-03-10 2025-03-06 B Purchase
1.7
McNamara Robert
Non-Executive Director
11,000 +24.0%
8.30
US$91,300 		11,000 +24.0% 8.30 US$91,300
2025-02-20 2025-02-20 B Purchase
1.7
McNamara Robert
Non-Executive Director
10,000 +28.0%
10.09
US$100,900 		10,000 +28.0% 10.09 US$100,900
2025-02-20 2025-02-20 B Purchase
2.7
O'Toole David D

CFO

Officer
1,000 +4.0%
9.90
US$9,900 		1,000 +4.0% 9.90 US$9,900
2025-02-19 2025-02-19 B Purchase
2.7
O'Toole David D

CFO

Officer
1,000 +4.2%
10.25
US$10,250 		1,000 +4.2% 10.25 US$10,250
2025-01-29 2024-12-09 B Purchase
0.5
Crowe Suzanne
Non-Executive Director
486 +1.3%
13.15
US$6,391 		486 +1.3% 13.15 US$6,391
2024-12-05 2024-12-05 B Purchase
2.7
O'Toole David D

CFO

Officer
500 +2.2%
12.40
US$6,200 		500 +2.2% 12.40 US$6,200
2024-12-05 2024-12-05 B Purchase
2.7
O'Toole David D

CFO

Officer
475 +2.1%
12.53
US$5,952 		475 +2.1% 12.53 US$5,952
2024-06-03 2024-05-30 B Purchase
2.7
O'Toole David D

CFO

Officer
500 +2.6%
8.60
US$4,300 		500 +2.6% 8.60 US$4,300
2024-06-03 2024-05-30 B Purchase
2.7
O'Toole David D

CFO

Officer
500 +2.7%
9.20
US$4,600 		500 +2.7% 9.20 US$4,600
2024-02-28 2024-02-28 B Purchase
2.7
O'Toole David D

CFO

Officer
250 +1.4%
17.43
US$4,358 		250 +1.4% 17.43 US$4,358
2024-02-28 2024-02-28 B Purchase
2.7
O'Toole David D

CFO

Officer
1,000 +5.7%
17.38
US$17,380 		1,000 +5.7% 17.38 US$17,380
2023-12-27 2023-12-26 S Sale
1.5
CORBETT JAMES

CEO

Executive Director
1,445 -11.1%
13.29
US$19,204 		1,445 -11.1% 13.29 US$19,204
2023-12-28 2023-12-22 S Sale Jeremy Curnock Cook Director
2,500
12.05
A$30,121 		2,500 12.05 A$30,121
2023-12-14 2023-12-13 S Sale
1.3
COOK JEREMY CURNOCK
Non-Executive Director
2,518 -10.9%
12.27
US$30,896 		2,518 -10.9% 12.27 US$30,896
2023-12-12 2023-12-12 B Purchase
2.7
O'Toole David D

CFO

Officer
950 +5.7%
12.45
US$11,828 		950 +5.7% 12.45 US$11,828
2023-12-04 2023-12-01 B Purchase
2.7
O'Toole David D

CFO

Officer
500 +3.1%
10.68
US$5,340 		500 +3.1% 10.68 US$5,340
2023-11-21 2023-11-21 B Purchase
2.7
O'Toole David D

CFO

Officer
1,000 +7.1%
10.26
US$10,260 		1,000 +7.1% 10.26 US$10,260
2023-11-21 2023-11-21 B Purchase
2.7
O'Toole David D

CFO

Officer
1,000 +7.7%
10.30
US$10,300 		1,000 +7.7% 10.30 US$10,300
2023-11-16 2023-11-16 B Purchase
2.7
O'Toole David D

CFO

Officer
1,000 +9.1%
12.15
US$12,150 		1,000 +9.1% 12.15 US$12,150
2023-11-16 2023-11-15 B Purchase
2.7
O'Toole David D

CFO

Officer
1,000 +8.3%
12.45
US$12,450 		1,000 +8.3% 12.45 US$12,450
2023-11-15 2023-11-15 B Purchase
2.7
O'Toole David D

CFO

Officer
1,000 +10.0%
13.25
US$13,250 		1,000 +10.0% 13.25 US$13,250
2023-11-15 2023-11-14 B Purchase
2.7
O'Toole David D

CFO

Officer
1,000 +11.1%
12.88
US$12,880 		1,000 +11.1% 12.88 US$12,880
2023-09-08 2023-08-21 S Sale
3.1
Shiroma Donna

General Counsel

Officer
4,193 -9.0%
15.84
US$66,417 		4,193 -9.0% 15.84 US$66,417
2023-08-16 2023-08-16 B Purchase
2.7
O'Toole David D

CFO

Officer
1,000 +12.5%
17.06
US$17,060 		1,000 +12.5% 17.06 US$17,060
2023-08-16 2023-08-16 B Purchase
2.7
O'Toole David D

CFO

Officer
1,000 +14.3%
17.05
US$17,050 		1,000 +14.3% 17.05 US$17,050
2023-08-15 2023-08-15 B Purchase
2.7
O'Toole David D

CFO

Officer
1,000 +16.7%
17.93
US$17,930 		1,000 +16.7% 17.93 US$17,930
2023-08-15 2023-08-15 B Purchase
2.7
O'Toole David D

CFO

Officer
1,000 +20.0%
17.94
US$17,940 		1,000 +20.0% 17.94 US$17,940
2023-08-15 2023-08-15 B Purchase
2.7
O'Toole David D

CFO

Officer
1,000 +25.0%
17.96
US$17,960 		1,000 +25.0% 17.96 US$17,960
2023-08-15 2023-08-15 B Purchase
2.7
O'Toole David D

CFO

Officer
1,000 +33.3%
17.89
US$17,890 		1,000 +33.3% 17.89 US$17,890
2023-08-15 2023-08-15 B Purchase
2.7
O'Toole David D

CFO

Officer
1,000 +50.0%
17.92
US$17,920 		1,000 +50.0% 17.92 US$17,920
2023-06-21 2023-06-20 B Purchase
2.7
O'Toole David D

CFO

Officer
1,000 +100.0%
16.15
US$16,150 		1,000 +100.0% 16.15 US$16,150
2023-06-08 2023-06-08 PrS Proposed sale
Liberto Erin

Officer

Officer
122,531
17.00
US$2,083,027 		122,531 17.00 US$2,083,027
2022-11-29 2022-11-22 S Sale Michael Perry Director
15,000,000
5.99
US$89,850,000 		15,000,000 5.99 US$89,850,000
2022-11-22 2022-11-21 S Sale
2.3
PERRY MICHAEL S
Non-Executive Director
150,000 -39.5%
7.18
US$1,077,000 		150,000 -39.5% 7.18 US$1,077,000
2022-03-03 2022-02-25 S Sale Michael Perry Director
2,386,116
8.72
US$20,806,932 		2,386,116 8.72 US$20,806,932
2022-02-25 2022-02-24 S Sale
2.3
PERRY MICHAEL S

Chief Executive Officer

Executive Director
10,812 -3.3%
8.74
US$94,497 		10,812 -3.3% 8.74 US$94,497
2021-09-09 2021-09-01 S Sale Michael Perry Director
2,386,823
20.62
US$49,216,290 		2,386,823 20.62 US$49,216,290
2021-06-08 2021-06-04 S Sale Michael Perry Director
4,824,377
17.57
US$84,764,304 		4,824,377 17.57 US$84,764,304
2021-06-04 2021-06-02 S Sale
2.3
PERRY MICHAEL S

Chief Executive Officer

Executive Director
23,000 -9.3%
17.33
US$398,590 		23,000 -9.3% 17.33 US$398,590
2021-03-29 2021-03-22 S Sale Michael Perry Director
631,523
5.51
A$3,479,692 		631,523 5.51 A$3,479,692
2020-09-16 2020-09-16 S Sale
2.3
PERRY MICHAEL S

Chief Executive Officer

Executive Director
9,000 -2.1%
27.41
US$246,690 		9,000 -2.1% 27.41 US$246,690
2020-09-16 2020-09-15 S Sale
2.3
PERRY MICHAEL S

Chief Executive Officer

Executive Director
23,769 -5.2%
27.23
US$647,230 		23,769 -5.2% 27.23 US$647,230
2020-09-16 2020-09-14 S Sale
2.3
PERRY MICHAEL S

Chief Executive Officer

Executive Director
15,092 -3.2%
26.99
US$407,333 		15,092 -3.2% 26.99 US$407,333
2020-09-11 2020-09-11 S Sale
2.3
PERRY MICHAEL S

Chief Executive Officer

Executive Director
20,000 -4.7%
26.02
US$520,400 		20,000 -4.7% 26.02 US$520,400
2020-09-11 2020-09-10 S Sale
2.3
PERRY MICHAEL S

Chief Executive Officer

Executive Director
7,128 -1.7%
26.26
US$187,181 		7,128 -1.7% 26.26 US$187,181
2020-07-21 2020-07-17 B Purchase
2.2
McIntyre David

Chief Financial Officer

Officer
393 +78.6%
22.70
US$8,921 		393 +78.6% 22.70 US$8,921
2020-07-21 2020-07-16 B Purchase
2.2
McIntyre David

Chief Financial Officer

Officer
300 +150.0%
23.85
US$7,155 		300 +150.0% 23.85 US$7,155
Explore more

More insider trading research around AVITA Medical Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America